DSPE Regulatory Update: Acceptance Of The European Medicines Agency Submission For An Atypical Antipsychotic Agent Lurasidone

Date: Oct-27-2012Dainippon Sumitomo Pharma Europe Ltd ("DSPE") (Headquarters: London, UK) today
announced that the European Medicines Agency (EMA) has confirmed that the Marketing
Authorisation Application (MAA) for lurasidone hydrochloride, an atypical antipsychotic
investigational medicine for the treatment of schizophrenia, is valid.

The MAA was filed by Takeda Global Research & Development Centre (Europe). Dainippon
Sumitomo Pharma Co., Ltd ("DSP") discovered and developed lurasidone. Takeda entered into
a license agreement with DSP stipulating the joint development and granting of an
exclusive commercialisation right of the product to Takeda in 26 member states of the
European Union (excluding the United Kingdom), and Switzerland, Norway, Turkey and Russia
in March 2011. DSPE will be undertaking the commercialisation of lurasidone in the UK.

The MAA submission is based on data from more than 50 clinical trials involving more
than 3,800 subjects. Phase 3 clinical trials, demonstrated significantly greater
improvement in the primary efficacy endpoint [Positive and Negative Syndrome Scale
(PANSS)]* total score in patients with schizophrenia treated with lurasidone administered
once daily versus placebo. The most commonly observed adverse reactions in patients
treated with lurasidone were somnolence, akathisia, nausea and parkinsonism. Lurasidone
was generally well-tolerated with minimal effect on weight or metabolic parameters.

"Lurasidone is anticipated to be a core product for the expansion of the DSP Group,
and I am very pleased that we have achieved the important milestone of submitting an MAA
in Europe." said Masayo Tada, President and Chief Executive Officer of Dainippon Sumitomo
Pharma Co., Ltd. "Through the cooperation between our companies, we are working towards a
swift approval in order to make this investigational medicine available as soon as
possible."

* A medical scale used for mainly measuring symptom severity of patients with
schizophrenia. It consists of 30 items---7 items of positive scale, 7 items of negative
scale and 16 items of general psychopathology scale. Each item is rated from 1 (absent) to
7 (extreme).

About lurasidone

Lurasidone is an atypical antipsychotic, developed originally by DSP with an affinity
for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist
effects. Lurasidone is a partial agonist at the serotonin 5-HT1A receptor and has no
appreciable affinity for histamine or muscarinic receptors.

Lurasidone (brand name LATUDA(R)) was approved for the treatment of schizophrenia by
the United States Food and Drug Administration on 28 October 2010 and by Health Canada on
13 June 2012. LATUDA was launched in the United States for the treatment of schizophrenia
in adults on February 4, 2011 (US time) and in Canada on September 17, 2012 (Canada Time)
through DSP's subsidiary Sunovion Pharmaceuticals Inc.

View drug information on Latuda.
Courtesy: Medical News Today Note: Any medical information available in this news section is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.